The official letter 12312/QLD-TT Provide the safety information of Gadolinium-containing contrast agents; Codeine, Tramadol-containing drugs; Hyoscine butylbromide injections; Risperidone-containing drugs; Skin antiseptic chlorhexidine gluconate

398
The official letter 12312/QLD-TT
The official letter 12312/QLD-TT
The official letter 12312/QLD-TT Provide the safety information of Gadolinium-containing contrast agents; Codeine, Tramadol-containing drugs; Hyoscine butylbromide injections; Risperidone-containing drugs; Skin antiseptic chlorhexidine gluconate
5 (100%) 1 vote
MINISTRY OF HEALTH

DRUG ADMINISTRATION OF VIET NAM

————————

SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

——o0o—–

N0 12312/QLD-TT
About: Provide the safety information of Gadolinium-containing contrast agents; Codeine, Tramadol-containing drugs; Hyoscine butylbromide injections; Risperidone-containing drugs; Skin antiseptic chlorhexidine gluconate Hanoi, August 15, 2017

 

To:       – Provincial/Municipal Health Services

– Hospitals, institutes with beds directly under Ministry of Health

 

On May 19, 2017, Drug Registration Advisory Council met to approve registration stage 158th for domestic drugs and stage 97th for foreign drugs and unify to update the safety information of: Gadolinium-containing contrast agents; Codeine, Tramadol-containing drugs; Hyoscine butylbromide injections; Risperidone-containing drug; Skin antiseptic chlorhexidine gluconate.

In order to ensure the safe and effective use of drugs, Drug Administration of Vietnam requests Provincial/Municipal Health Services, Hospitals, institutes with beds directly under Ministry of Health as follow:

  1. Notify medical facilities, pharmaceutical business facilities in respective localities about the safety and efficacy information of above drugs as prescribed in Annex “Update the safety information of drugs” enclosed with this Official Letter; At the same time, it is uploaded on the portal of the Drug Administration of Vietnam at http://www.dav.gov.vn in the section “Drug information” so that healthcare professionals may search and update information.
  2. Guiding medical facilities in respective localities to enhance monitoring, detection and management the adverse drug reactions of above drugs (if any) and report ADR to NationalDI & ADR Centre (13-15 Le Thanh Tong, Hanoi) or Regional Centre forDrug Information and Adverse Drug Reactions Monitoring in Ho Chi Minh City (201B Nguyen Chi Thanh, Dis.5, Ho Chi Minh City).

Drug Administration of Vietnam will continue update the safety information and management guideline of ADR of above drugs to request Drug registration applicants updating information to the label and package insert.

Drug administration of Vietnam notifies the facilities to know and comply.

For General Director

Vice General Director

(Signed and Sealed)

Nguyen Tat Dat

The official letter 12312/QLD-TT Provide the safety information of Gadolinium-containing contrast agents; Codeine, Tramadol-containing drugs; Hyoscine butylbromide injections; Risperidone-containing drugs; Skin antiseptic chlorhexidine gluconate

DOWNLOAD FOR FULL ENGLISH VERSION

12312_QLD_TT_VNRAS_ENGLISH

COPY PLEASE REFER TO VNRAS.COM

TRANSLATED BY MINH VAN

LEAVE A REPLY

Please enter your comment!
Please enter your name here